Abstract
The prevalence of testosterone deficiency syndrome (TDS) is significant in men > 40 years of age. TDS is a significant health problem because, based on the association of low testosterone (T) levels with diabetes, cardiovascular disease, and osteoporosis, it leads to reduced length and quality of life.
Hypogonadal men with ED die earlier than androgen-adequate men, and CVD and DM2T play a major role in this. The diagnosis of TDS requires the presence of clinical manifestations and laboratory confirmation of an abnormal T level.
If the diagnosis of TDS is confirmed, lifestyle modification and injectable, oral or transdermal T substitution is recommended. The patient must be regularly monitored by performing a physical examination, comprehensive serum analysis and DRE.
The benefit of TRT for the patient is the achievement of physiological T levels, improvement of sexual function, muscle strength and mass, increase of energy, bone density, feeling of well-being and improvement of cardiovascular morbidity. Considering that deaths from cardiovascular diseases are still at the top of the imaginary list, the diagnosis of late-onset hypogonadism is important from the point of view of reducing morbidity and mortality from CVD as well as improving the quality of life of men with LOH.
It is extremely important to monitor the testosterone levels of patients who have experienced COVID-19, in patients with a more severe course of COVID-19, a low level of testosterone was found, which predicted a more severe course and/or death.